Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Impact of elraglusib (9-ING-41) treatment on gene expression in human colorectal cancer and immune cell lines.

ABSTRACT: A growing body of literature evaluates the potential anti-cancer and immunostimulatory effects of GSK-3 inhibition. Accordingly, we sought to evaluate GSK-3 inhibitor elraglusib (9-ING-41) and its impact on gene expression in both human colorectal cancer (CRC) cell lines and human immune cell lines. We used microarrays to detail the differential gene expression that occurs post-treatment with GSK-3 inhibitor 9-ING-41 (elraglusib).

ORGANISM(S): Homo sapiens

PROVIDER: GSE222849 | GEO | 2023/02/16

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

9-ING-41 in Patients With Advanced Cancers

Project description:GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.

| 2284734 | ecrin-mdr-crc

9-ING-41, a small molecule inhibitor of GSK-3β, potentiates the effects of chemotherapy in KRAS mutated colorectal cancer

Project description:Despite the prevalence of KRAS mutations in colorectal cancer, there is no K-Ras targeted therapies for these tumors and available treatment options are limited for metastatic disease. GSK-3β has been demonstrated to be a critically important kinase for survival and proliferation of K-Ras-depended pancreatic cancer cells. In this study we tested 9-ING-41, a small molecule inhibitor of GSK-3β, in patient-derived tumor organoid models of colorectal cancer. We demonstrated that addition of 9-ING-41 to the standard of care drugs 5-FU and oxaliplatin could significantly enhance inhibition of the growth of colorectal cancer cells harboring KRAS mutations. The results of the transcriptomic analysis support our findings of cell cycle arrest and DNA repair deficiency in 9-ING-41-treated colorectal cancer cells. Moreover, we found substantial similarity in the changes of transcriptomic profile after inhibition of GSK-3β and suppression of STK33, another critically important kinase for K-Ras-dependent cells. Overall, the results of this study provide a rationale for the inclusion of patients with mutant KRAS colorectal cancer in clinical studies of 9-ING-41 and other GSK-3 inhibitors.

2021-10-31 | GSE184125 | GEO

9-ING-41, a small molecule inhibitor of GSK-3β, potentiates the effects of chemotherapy in KRAS mutated colorectal cancer

Project description:9-ING-41, a small molecule inhibitor of GSK-3β, potentiates the effects of chemotherapy in KRAS mutated colorectal cancer

| PRJNA763229 | ENA

Impact of elraglusib (9-ING-41) treatment on gene expression in human colorectal cancer and immune cell lines.

Project description:Impact of elraglusib (9-ING-41) treatment on gene expression in human colorectal cancer and immune cell lines.

| PRJNA923655 | ENA

ATAC-seq analysis for DND-41 and MOLT4 cells with ACBI-1 treatment

Project description:ATAC-seq analysis was performed in two T-ALL cell lines (DND-41 and MOLT-4) with either DMSO or ACBI-1 treatment at two different time points (3hr and 24hr).

2024-07-02 | GSE230584 | GEO

Vibrio parahaemolyticus strain:41-1 | isolate:41-1

Project description:Vibrio parahaemolyticus strain:41-1 | isolate:41-1 Genome sequencing and assembly

| PRJNA915930 | ENA

Vibrio parahaemolyticus strain:41-2 | isolate:41-2

Project description:Vibrio parahaemolyticus strain:41-2 | isolate:41-2 Genome sequencing and assembly

| PRJNA915931 | ENA

RNA-seq analysis after 24hr of ACBI-1 treatment on DND-41 and MOLT-4 cells.

Project description:RNA-seq analysis was performed in two T-ALL cell lines (DND-41 and MOLT-4) to analyze gene expression changes after 24 hours of 100nM ACBI-1 or DMSO treatment.

2024-07-02 | GSE230590 | GEO

RNA-seq analysis after 8hr of ACBI-1 treatment on DND-41 and MOLT-4 cells.

Project description:RNA-seq analysis was performed in two T-ALL cell lines (DND-41 and MOLT-4) to analyze gene expression changes after 8 hours of 100nM ACBI-1 or DMSO treatment.

2024-07-02 | GSE230589 | GEO

RNA-seq analysis after 3hr of ACBI-1 treatment on DND-41 and MOLT-4 cells.

Project description:RNA-seq analysis was performed in two T-ALL cell lines (DND-41 and MOLT-4) to analyze gene expression changes after 3 hours of 100nM ACBI-1 or DMSO treatment.

2024-07-02 | GSE230588 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data